t e C h n I C a l r e p O r t S A fundamental impediment to understanding the brain is the availability of inexpensive and robust methods for targeting and manipulating specific neuronal populations. The need to overcome this barrier is pressing because there are considerable anatomical, physiological, cognitive and behavioral differences between mice and higher mammalian species in which it is difficult to specifically target and manipulate genetically defined functional cell types. In particular, it is unclear the degree to which insights from mouse models can shed light on the neural mechanisms that mediate cognitive functions in higher species, including humans. Here we describe a novel recombinant adenoassociated virus that restricts gene expression to GABAergic interneurons within the telencephalon. We demonstrate that the viral expression is specific and robust, allowing for morphological visualization, activity monitoring and functional manipulation of interneurons in both mice and non-genetically tractable species, thus opening the possibility to study GABAergic function in virtually any vertebrate species.
Inhibitory GABAergic interneurons, although sparser in number than glutamatergic neurons, play critical roles in all central processing, and their dysfunction contributes to numerous neuropsychiatric disorders [1] [2] [3] . To date, the ability to target interneurons has been essentially limited to the use of transgenic mice 4 . While certain cell types, such as principal excitatory cells and glia, have been successfully targeted [5] [6] [7] , an effective approach to target inhibitory interneurons is not currently available. Gene delivery using nonpathogenic recombinant adeno-associated virus (rAAV) is showing increasing promise for the treatment of both monoallelic and complex diseases. Many phase I-III clinical trials using rAAV vectors have yielded encouraging results, and in 2012, the first rAAV-based therapy received marketing approval from the European Union 8 . Despite its promise, the use of AAV as a gene-delivery method is hampered by its limited selectivity in expression. While it has been long recognized that including cis-acting DNA control elements [9] [10] [11] [12] [13] [14] , such as specific promoters or enhancers, within rAAVs might provide the desired specificity for expression within particular target cells in the brain, the success of such strategies has been limited. With regard to rAAVs, the chief obstacle to this approach is the fundamental incompatibility of the size of such control elements relative to the restricted packaging limit of AAVs 15, 16 . Given the obligate minimal size of reporters (for example, EGFP or dTomato) alone or in combination with effector elements (for example, ChR2 or DREADD), which average about 700 bp to 2 kb, respectively, a maximum of ~2 kb in packaging capacity remains for the insertion of a cis-acting DNA control element into the viral vector. In order to identify sufficiently small elements capable of restricting expression to a defined population of cells, we examined regulatory elements known in other contexts to be specific to interneurons [17] [18] [19] . The distalless homeobox 5 and 6 (Dlx5/6) genes are specifically expressed by all forebrain GABAergic interneurons during embryonic development. These genes have an inverted orientation relative to one another and share a 400 bp (mI56i or mDlx) and a 300 bp (mI56ii) enhancer sequence in the 10 kb noncoding intergenic region 3′ to each of them 17, 20 . The high degree of conservation of these sequences across vertebrate species is suggestive of an important t e C h n I C a l r e p O r t S role in gene regulation. Indeed, the mDlx enhancer has been used in numerous contexts to reliably target reporter genes in a pattern very similar to the normal patterns of Dlx5/6 expression during embryonic development 17, [21] [22] [23] [24] .
RESULTS

The mDlx enhancer restricts reporter expression to GABAergic interneurons in vitro
We first aimed to determine whether the mDlx enhancer can restrict the expression of reporter genes to GABAergic interneuron in vitro using rAAV. We inserted the mDlx enhancer in front of a minimal promoter in an AAV backbone, using the genetically encoded calcium indicator GCaMP6f construct as a reporter to monitor expression (rAAV-mDlx-GCaMP6f). Primary cortical neuronal cultures from mice were infected with rAAV-mDlx-GCaMP6f, cultured for 11 d after infection and examined for GCaMP6f expression. We observed that the majority of cells that expressed GCaMP6f also expressed the pan-interneuron marker Gad67 (~95%; Fig. 1a,i) . As expected, expression of GCaMP6f driven by an rAAV containing a promoter that targets excitatory neurons (CaMK2a) was excluded from GABAergic interneurons ( Supplementary Fig. 1a ).
To test whether the level of GCaMP6f expression in interneurons was sufficient to allow their activity to be monitored, we performed in vitro calcium imaging. Consistent with their high level of expression, robust spontaneous calcium transients could be detected in primary culture of cortical neurons in vitro (Supplementary Fig. 1b ). Taken together, these data demonstrate that the mDlx enhancer alone was sufficient both to restrict the expression of a reporter to interneurons and to allow monitoring of neuronal activity of interneurons in vitro when used to direct GCaMP6f expression.
The mDlx enhancer restricts reporter expression to adult GABAergic interneurons in the forebrain A number of aspects of Dlx5/6 gene expression compromise their utility as markers for interneurons. Dlx5/6 genes are highly expressed in progenitors of GABAergic and postmitotic interneurons during embryonic development, but their expression strongly diminishes after birth. Moreover, in the striatum these genes are not specific to interneurons, as both interneurons and medium spiny neurons (4% and 96% of the population, respectively; medium spiny neurons are the principal projection neurons) express high levels of Dlx5/6 during embryonic development 17, 18, 25 . Groups that have used the mDlx enhancer in transgenic mice have found that reporters under the control of this element are faithfully expressed in a pattern that closely matches endogenous patterns of Dlx5/6 expression, demonstrating the unsuitableness of using this approach to either label interneurons postnatally or to differentiate between interneurons and medium spiny neurons within the striatum 17, [21] [22] [23] [24] . This prompted us to test whether rAAV-mDlx-GFP virus had similar limitations in its ability to target interneuronal populations. Unexpectedly, immunofluorescence analyses of adult mice 1 week after injection with rAAV-mDlx-GFP revealed sparse but strong GFP labeling in somatosensory cortex (S1), hippocampus and striatum ( Fig. 1b) , indicative of the labeling of interneurons. To confirm the identity of these cells, we injected rAAV-mDlx-GFP into the cortex and hippocampus of Dlx6aCre:Ai9 mice, where the persistence of the RFP reporters subsequent to the cessation of Dlx6 expression results in all interneurons within these areas being RFP-positive. Again, the majority of GFP-expressing cells coexpressed RFP ( Fig. 1c,d,j) . Moreover, rAAV-mDlx-GFP expression within the striatum colocalized with Nkx2.1, an interneuron marker within this structure ( Fig. 1e,k) . Consistent with the expression of GFP being uniformly observed within all interneuron populations, within S1, the infected cells expressed parvalbumin, somatostatin and vasoactive intestinal peptide (VIP) in proportions that corresponded to the expected layer distribution of these three non-overlapping interneuron markers in this region 1, 26 ( Fig. 1f-h,i) . To investigate whether the mDlx enhancer could also drive expression in interneurons not derived from the Dlx5/6 lineage, we performed viral injections in the lumbar region of the spinal cord of postnatal day 0 pups and analyzed the expression of the viral reporter after 7 d. In mice injected with rAAV-mDlx-GFP, the GFP expression appeared to be restricted to the dorsal horns of the lumbar spinal cord, and virtually no cells expressing the viral reporter colocalized with Pax2, a marker exclusively expressed in virtually all GABAergic and glycinergic interneurons of the dorsal horns of the spinal cord in both embryonic and adult animals 27 . By contrast, mice injected with an AAV expressing nuclear GFP under the control of the pan-neuronal promoter human synapsin1 (rAAV-hSyn1-nGFP) showed widespread expression of GFP within both ventral and dorsal spinal cord, with ~12% of cells colocalizing with Pax2 ( Supplementary Fig. 2) . These data show that the expression driven by the mDlx enhancer was excluded from the inhibitory neurons in the spinal cord, but restricted to a population of cells in the dorsal spinal cord that remains to be characterized. Altogether, these results demonstrate that infection of adult mice with rAAV-mDlx-GFP resulted in a highly selective expression within GABAergic interneurons from the Dlx5/6 lineage within the telencephalon.
rAAV-mDlx-Flex-GFP allows for the intersectional targeting of interneuron subtypes Despite significant progress in recent years, the precise targeting and manipulation of specific interneuron subtypes is still essentially limited to the combinatorial use of transgenic mice expressing Cre and Flp recombinases in defined populations 4, 28 . The specificity of targeting is thus hampered by the availability of driver lines and the timeconsuming breeding associated with generating productive crosses on suitable genetic backgrounds. Therefore, we asked whether the specificity of the rAAV-Dlx for interneurons could be leveraged to develop an intersectional strategy that would require only one Creexpressing mouse reporter. To test this idea, we injected an rAAV that expressed a Cre-dependent GFP reporter under the control of the mDlx enhancer (rAAV-mDlx-Flex-GFP) into Cck-Cre transgenic mice. While Cck is expressed in specific subsets of interneurons, its broader expression within glutamatergic neurons limits the usefulness of Cck-Cre mice for targeting interneurons 4 . In both somatosensory cortex S1 and hippocampal CA1, the majority of cells expressing GFP coexpressed the pan-interneuron marker Gad67 (Fig. 2) . Importantly, Cck-Cre mice injected with an rAAV that expressed a Cre-dependent GFP reporter under the control of an ubiquitous promoter (rAAV-CAG-Flex-GFP) showed that the GFP expression was not selective for interneurons, and animals that do not express Cre-recombinase injected with rAAV-mDlx-Flex-GFP did not show GFP expression at the injection site ( Supplementary Fig. 3 ). These data demonstrate that the mDlx enhancer restricted the expression of a recombinasedependent reporter to interneurons and can be used as a simplified intersectional strategy. Importantly, to test whether Cre-recombinase itself can be selectively directed by this approach, we injected an rAAV that expressed nuclear dTomato and Cre or destabilized Cre under the control of the mDlx enhancer (rAAV-mDlx-Cre or rAAV-mDlx-dCre) into RCE-loxP transgenic mice. While dTomato was confined to the interneuron population, in animals injected with Cre and dCre virtually all cells expressed GFP at the injection site (data not shown). t e C h n I C a l r e p O r t S This demonstrates that trace amounts of Cre-recombinase were sufficient to drive expression of a Cre-dependent genetic reporter and thus suggests that specificity of expression of recombinases cannot be achieved using this approach.
rAAV-hDLX-Gq-DREADD allows for chemogenetic modulation of interneuronal activity
Having established that our strategy enabled high expression of fluorescent reporters (GFP) and activity indicators (GCaMP6f) restricted to interneurons, we next sought to examine whether chemogenetic approaches could be used to manipulate interneuron activity. Designer receptors exclusively activated by designer drugs (DREADDs) are modified human muscarinic receptors that are activated by clozapine-N4-oxide (CNO), a pharmacologically inert and orally bioavailable drug 29 . To date, their utilization in interneurons has been restricted to contexts involving the use of transgenic mice [30] [31] [32] [33] . To test whether we could use rAAV-hDlx to gain chemogenetic control of interneurons, we generated an rAAV-hDlx-Gq expressing a hemagglutinin Dlx6a-Cre::Ai9, S1: 92.8 ± 1.2%, n = 657 cells from 4 animals; GFP + RFP + : Dlx6a-Cre::Ai9, CA1: 91.8 ± 0.9%, n = 210 cells from 4 animals; GFP + Nkx2.1 + : C57Bl6, in striatum: 36.4 ± 2.6%, n = 284 cells from 3 animals; GFP + Pvalb + : C57Bl6, in S1: layer (L) 2/3: 26.9 ± 2.5%; in L4: 37.7 ± 5.1%; in L5/6: 45.1 ± 3.2%; total n = 577 from 3 animals; GFP + Sst + : C57Bl6, in S1: in L2/3: 17.8 ± 2.3%; in L4: 32.3 ± 1.6%; in L5/6: 35.4 ± 3.0%; total n = 577 from 3 animals; GFP + VIP + : C57Bl6, in S1: in L2/3: 32.6 ± 3.3%; in L4: 20.0 ± 3.4%; in L5/6: 14.6 ± 3.0%; total n = 701 from 4 animals. Quantification are indicated in the text as mean ± s.e.m. and are represented as box-and-whisker plot with upper and lower whiskers representing the maximum and minimum value respectively while the boxes represent upper, median and lower quartiles. Fig. 4a ).
We first tested whether the use of the human form of the Dlx5/6 enhancer (hDlx) negatively impacted the targeting specificity of the virus. Immunofluorescence analyses of adult Dlx6aCre::RCE mice (where GFP expression in the cortex and hippocampus was restricted to interneurons) injected with rAAV-hDlx-Gq in S1 and CA1 revealed that the majority of cells expressing dTomato also expressed GFP Supplementary Fig. 4b-d ). In addition, consistent with the expected expression of a functional receptor, the Gq-DREADD was located at the membrane of the infected cells ( Fig. 3a and Supplementary Fig. 4e ). These data confirm that rAAV-hDlx-Gq drove the expression of the Gq-DREADD exclusively within interneurons. We then formally tested the functionality of the Gq-DREADD within these cells. Upon bath application of CNO, all interneurons expressing Gq-DREADD showed membrane potential depolarization in less than 1 min, consistent with the expression of a functional receptor (Fig. 3b,c) . Finally, voltage clamp recordings of a pyramidal cell in the vicinity of the Gq-DREADD-expressing interneurons showed an increase in inhibitory postsynaptic currents (iPSCs) upon CNO application ( Fig. 3d,e) . These experiments demonstrate that rAAV-mDlx-Gq allowed functional and restricted expression of Gq-DREADD and that CNO treatment effectively and selectively increased the activity of interneurons, allowing localized and pronounced increases in inhibitory tone within neighboring excitatory neurons.
rAAV-mDlx is selectively expressed within GABAergic interneurons in a wide variety of vertebrate species
The high degree of conservation of the mDlx enhancer sequence across vertebrates suggests a conserved role in the transcriptional regulation of the Dlx5/6 genes 20 . We thus sought to test whether the use of rAAV-Dlx could be extended to direct the expression of a variety of different reporters and effectors, specifically in interneurons in non-genetically tractable species. This proved successful, as we were able to achieve both comparable levels and the fidelity of expression of rAAV-Dlx in neurons from five different species. Similarly to what has been observed in mice, the expression of GFP or RFP in zebra finches, ferrets, gerbils and marmosets infected with rAAV-Dlx colocalized with cells expressing the pan-interneuron markers GABA or Gad67 ( Fig. 4a-d) . Most relevant to humans, infection of neurons obtained from patient-derived induced pluripotent stem cells with rAAV-mDlx-GFP showed that the majority of the cells expressing GFP coexpressed GABA (Fig. 5a) . To confirm these findings, we introduced rAAV-hDlx-dTomato into a coculture containing both dorsalized human embryonic stem cells (hESCs; mainly glutamatergic neurons), as well as a transgenic hESC reporter line expressing Citrine specifically in t e C h n I C a l r e p O r t S interneurons derived from the medial ganglionic eminence (hESC-Lhx6-Citrine). Immunostaining analysis showed that the majority of cells expressing the nuclear dTomato also expressed Citrine, while none of the dorsalized hESCs expressed dTomato (Fig. 5b) . These results show that the Dlx enhancer restricted rAAV-mediated gene expression to interneurons in all vertebrate species tested, including human. In addition, slice and in vivo recordings from zebra finches injected with rAAV-mDlx-GFP showed that the GFP-expressing cells exhibited electrophysiological and morphological properties characteristic of interneurons (Supplementary Fig. 5 ). The success of this approach further highlights the potential of rAAV-Dlx for identifying and characterizing interneuron subtypes in non-genetically tractable animal models. Using in vitro slice recordings from gerbils injected with rAAV-mDlx-ChR2-mCherry in the auditory cortex (A1), we showed that 1-ms pulses of blue light elicited action potentials in cells expressing mCherry (Supplementary Fig. 6a,b) .
As expected, voltage-clamp recording of noninfected cells in the vicinity of the injection site showed an abrupt interruption of action potentials upon light activation (Supplementary Fig. 6c,d) . rAAV-mDlx-ChR2-mCherry thus allows local optogenetic control of interneurons. In vivo calcium imaging of ferret visual cortex injected with rAAV-mDlx-GCaMP6f showed activation of interneurons upon presentation of visual stimuli (Supplementary Fig. 7) . This demonstrated that it is possible to use this tool to monitor the functional activity of neurons in the living brain while presenting behaviorally relevant stimuli to the animal.
DISCUSSION
Transgenic approaches in mice have revolutionized our understanding of circuits. However, it is presently impossible to efficiently and reliably identify and manipulate specific neuronal subtypes in non-genetically tractable species. Here we report a new approach that directly address this challenge. rAAVs have been previously used as a safe and effective gene delivery method by researchers and clinicians in numerous contexts, but their use has been hampered by the limited cell-type selectivity that can be achieved by natural or engineered tropism 8 . Another major limitation of rAAVs is their naturally limited DNA payload (~4.7 kb). This has reduced the range of regulatory sequences that can be used to achieve cellular specific expression 15 . One way to circumvent this limitation is to use short cis-regulatory sequences that can regulate gene expression. Enhancers are cis-acting elements composed of transcription factor binding sites that are responsible for tissue-specific transcriptional regulation of gene expression. Several laboratories have taken advantage of the high degree of conservation of noncoding genomic sequences to identify putative enhancers with conserved activity between mice and humans 19, 34 . The mouse Dlx5/6 enhancer is composed of a core sequence of 297 nucleotides showing t e C h n I C a l r e p O r t S 98% identity with human and 75% identity with zebrafish; it has been extensively used to drive gene expression exclusively in interneurons in various contexts 17, [21] [22] [23] [24] . An unexpected finding from this work is the differential activity of the mDlx or hDlx enhancers when used in transgenic contexts versus rAAV contexts. While the enhancer used in the context of rAAVs continues to direct interneuron expression in adult mice, it fails to do so endogenously or in transgenic animals. It seems likely that a combination of transcription factors cooperates to direct the expression of Dlx5/6 during embryonic development.
The loss of Dlx5/6 expression in adults is most likely either a result of a decrease in expression level of the transcription factors that bind and activate the mDlx enhancer or a result of the enhancer itself being epigenetically silenced postnatally. Either possibility is tenable, as the virus may escape epigenetic silencing by being episomal, or the large number of rAAV virions might be able to overcome reductions in transcription factor expression, such that rAAV expression can persist reliably in adults. Finally, in areas other than the telencephalon, this virus showed reliable expression, albeit in populations other than those expressing GABA. This likely reflects the presence within these cells of transcription factors able to specifically bind and activate the Dlx5/6 enhancer and opens the possibility to explore these cellular populations in the future. Questions of how the Dlx enhancer functions aside, our approach provides a toolbox for studying inhibitory GABAergic function across species in hippocampus, cortex and striatum and has strong potential for utility in clinical intervention. In particular, we showed that administration of CNO, the ligand for Gq-DREADD, selectively increased the activity of interneurons, resulting in an increase of local inhibition on neighboring excitatory pyramidal neurons. In mice, the use of optogenetic closed-loop recruitment of interneurons has proven effective for ameliorating seizures 35 . It has also been recently shown that reducing excitatory drive in pyramidal cells using Gi-DREADD can reduce the severity of seizures in mouse models of focal epilepsy 36 . The combination of the selectivity of rAAV-hDlx with the time control of Gq-DREADD thus allows for locally increasing the inhibitory drive of interneurons and could thus be beneficial to restore the excitatory-inhibitory balance in patients with intractable focal epilepsy.
Our results demonstrate that the mDlx enhancer can be used in the context of rAAVs to broadly and specifically target and manipulate interneurons from the Dlx5/6 lineage. Our success in targeting these interneurons in mice, zebra finches, ferrets, gerbils and marmosets, as well as in both human iPSC-derived and ESC-derived interneurons, illustrates the potential of this approach for extending our understanding of interneuron function across a broad range of species. This raises the question of whether this approach can be generalized to target additional neuronal populations. Other enhancers with a similar degree of conservation have been already been identified 34 , suggesting this might be possible. In addition, the emergence of high-throughput screening methods allowing genome-wide mapping of enhancers based on chromatin configuration and epigenetic marks has led to the discovery of many others 19, 37 . It is tempting to speculate that systematic screening of sequences for their ability to direct expression in specific cell types may provide an approach for the development of novel viral tools to target and manipulate individual functional cell types with unprecedented specificity.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Accession codes. Addgene: pAAV-mDlx-GFP, 83900; pAAV-mDlx-GCaMP6f, 83899; pAAV-mDlx-ChR2-mCherry, 83898; pAAV-hDlx-Gq-DREADD-dTomato, 83897; and pAAV-hDlx-Flex-GFP, 83895.
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ONLINE METHODS
Animals. Female C57BL/6J mice (Mus musculus; 10 weeks old) were obtained from Taconic (New York, NY). Adult male zebra finches (Taeniopygia guttata; 90 d after hatching) were obtained from an outside breeder and maintained in a temperature-and humidity-controlled environment with a 12/12-h light/dark schedule. Adult gerbils (Meriones unguiculatus; 85 to 95 d old) were obtained from breeding pairs from Charles River Laboratories (Cambridge, MA). Juvenile female ferrets (Mustela putorius furo; postnatal d 27-30) were obtained from Marshall Farms. For mice, zebra finches and ferrets, all animal maintenance and experimental procedures were performed according to the guidelines established by the Institutional Animal Care and Use Committee at the New York University Langone Medical Center. All procedures were approved by the Max Planck Florida Institute for Neuroscience Institutional Animal Care and Use Committee. One female marmoset (Callithrix jaccus; 4.3 years old) was obtained from the University of Utah. All procedures were approved by the Salk Institute for Biological Studies Institutional Animal Care and Use Committee. All procedures adhered to the standards of the National Institutes of Health. All the animals were maintained in a 12 light/12 dark cycle with a maximum of five animals per cage for mice and one animal per cage for all other species.
Surgery. Animals were anesthetized under isoflurane (1-3% in oxygen) and placed in a stereotactic head frame on a temperature-controlled heating pad. A craniotomy and a durotomy were performed above region of interest. The animals were injected with 50-500 nl of the indicated virus at a rate of 10-25 nl/min using a sharp glass pipette (25-35 mm in diameter), which was left in place for 5-15 min after the injection to minimize backflow. The craniotomy site was covered with sterile bone wax, the surgical opening was closed with Vetbond and the animals were returned to their home cages for at least 1 week. The injection sites were defined by the following coordinates: For zebra finches, the craniotomy was covered with a silicone elastomer (Kwik-Cast; WPI). For the subset of animals used for in vivo recording, a thin cover glass (3 mm, #1 thickness, Warner Instruments) was affixed to the skull using cyanoacrylate to create a chronic optical window over HVC. For ferrets, the scalp was retracted and a custom titanium head plate adhered to the skull using C&B Metabond (Parkell). One cover glass (5 mm in diameter, #1.5 thickness, Electron Microscopy Sciences) was adhered to a custom titanium cannula using optical adhesive (Norland Products) and placed onto the brain to gently compress the underlying cortex and dampen biological motion during imaging. The cranial window was hermetically sealed using a stainless steel retaining ring (5/16" or 7.94 mm) internal retaining ring, McMaster-Carr), Kwik-Cast (World Precision Instruments) and Vetbond (3M). For marmosets, the craniotomy was covered with an artificial dura made from bovine cells and the bone flap was fixed in place using Vetbond (3M). Following placement of the bone flap, the skin was sutured closed.
rAAV cloning and production. Detailed maps, sequences and plasmids corresponding to the viral constructs were deposited at Addgene. To clone these constructs, the plasmid AAV-CaMKIIa-GCaMP6f-P2A-nls-dTomato (a gift from Dr. Jonathan Ting; Addgene plasmid # 51087) was used to create a backbone containing either the mDlx or the hDlx enhancer sequences. The mDlx enhancer sequence (530 bp) was amplified by PCR from mouse genomic DNA using the following primers:
5′-TATACACTCACAGTGGTTTGGC-3′ and 5′-CTTCCTACTGTGAA ACTTTGGG-3′.
The hDlx enhancer sequence (541 bp) was amplified by PCR from human genomic DNA using the following primers:
5′-TTCAGAATGTTATGCACTCACA-3′ and 5′-CCCAAAGTTTCACAG TAGGAAG-3′.
The enhancers, reporters and effectors detailed below were subcloned using the Gibson Cloning Assembly Kit (NEB-E5510S) following standard protocol. For rAAV-mDlx-GFP, we amplified the GFP coding sequence from the plasmid pNeu-roD-ires-GFP 38 (a gift from Dr. Franck Polleux; Addgene plasmid # 61403). For rAAV-mDlx-Flex-GFP, we amplified the GFP coding sequence and synthetized the fragments containing the noncompatible loxP sites by primer annealing 39 . For rAAV-mDlx-GCaMP6f, we amplified the GCaMP6f coding sequence from the plasmid pGP-CMV-GCaMP6f 40 (a gift from Dr. Douglas Kim; Addgene plasmid # 40755). For rAAV-mDlx-ChR2, we amplified the ChR2 coding sequence from the plasmid pAAV-Ef1a-DIO hChR2(E123T/T159C)-EYFP 41 (a gift from Dr. Karl Deisseroth ; Addgene plasmid # 35509) fused with the mCherry coding sequence. For rAAV-hDlx-Gq-DREADD, we amplified the Gq-DREADD coding sequence from the plasmid pAAV-hSyn-DIO-hM3D(Gq)-mCherry 42 (a gift from Bryan Roth; Addgene plasmid # 44361) and a P2A-NLS-dTomato from the plasmid AAV-hSyn1-GCaMP6s-P2A-nls-dTomato (a gift from Jonathan Ting; Addgene plasmid # 51084). The rAAVs were produced using standard production methods. PEI was used for transfection and OptiPrep gradient (Sigma, USA) was used for viral particle purification. Titer was estimated by qPCR with primers for the WPRE sequence that is common to all constructs. All batches produced were in the range of 10 10 to 10 12 viral genomes per ml.
Primary culture. Primary dissociated cortical neurons were prepared from C57BL/6J mice at postnatal day 0 (P0) using a previously described protocol 43 . Dissociated neurons were plated onto coverslips precoated with polyethyleneimine (0.1%; Sigma, USA) plus laminin (20 µg/ml; Life Technologies, USA) at a density of 3,000 cells/mm 2 . The cultures were treated with AraC (1 µg/ml; Sigma, USA) on DIV 5 and maintained for up to 21 d after plating. All primary cultures were tested for mycoplasma contamination using standard protocol.
iPScs derived neuronal culture. The iPSC line iPSC49026 was generated at the NYSCF Research Institute by mRNA/miRNA reprogramming technology from skin fibroblasts of a deidentified male healthy donor 44 . The skin biopsy was obtained after institutional review board approval and receipt of informed consent. iPSCs were maintained in feeder-free conditions, seeded onto Matrigelcoated plates (BD Biosciences) in the presence of mTeSR1 medium (StemCell Technologies). The iPSC-derived neurons were generated using the Livesey protocol 45 with minor modifications: the protocol was followed exactly up to the differentiation step where BrainPhys medium was used with 1 µM dbcAMP, 40 ng/ml BDNF, 40 ng/ml GDNF and 1 µg/ml Laminin. At 50 DIV, the cells were inoculated with rAAV-mDlx-GFP at a MOI of ~150K vg/cell and fixed with 4% PFA at 60 DIV. All iPSC cultures were tested for mycoplasma contamination using standard protocol.
heScs derived neuronal culture. Lhx6-Citrine GABAergic interneurons were differentiated from an Lhx6-Citrine H9-reporter hESC line using a protocol as previously described 46 . Human excitatory neurons were obtained by forced expression of Ngn2 in a human iPSC line. At DIV 0, 200,000 hESC-Lhx6-Citrine interneurons and 200,000 Ngn2-induced excitatory neurons were plated on rat cortical feeders in a single 24-well. At DIV 1, the coculture was inoculated with rAAV-hDlx-Gq-DREADD at a MOI of 100,000 vg/cell and fixed at DIV 21. All cells were manipulated and cultured in a sterile environment using good cell culture practice and tested for mycoplasma using standard methods. All hESCs cultures were tested for mycoplasma contamination using standard protocol. electrophysiological recordings in mice. Slice preparation. Virally injected mice were anesthetized with intraperitoneal injection of pentobarbital (100 mg/kg body weight). Upon loss of reflexes, mice were transcardially perfused with icecold oxygenated ACSF containing the following (in mM): 87 NaCl, 75 sucrose, 2.5 KCl, 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 10 glucose, 1 CaCl 2 and 2 MgCl 2 . Mice were then decapitated and 300-µm thick coronal slices were sectioned using a Leica VT-1200-S vibratome and incubated in a holding chamber at 32-35 °C for 15-30 min followed by continued incubation at room temperature 20-23.5 °C (68-74 °F) for at least 45-60 min before physiological recordings. Slice containing the injection site were transferred in a recording chamber submerged with oxygenated ACSF containing the following (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 10 glucose, 2 CaCl 2 and 1 MgCl 2 (pH = 7.4, bubbled with 95% O2 and 5% CO2).
Current clamp. For interneuron recording, 10 µM CNQX, 25 µM AP-5 and 10 µM SR-95531 were also added to block AMPA, NMDA and GABA A receptors, respectively, to measure the cell-intrinsic effect of CNO application. Whole-cell current-clamp recordings were obtained from visually identified dTomato expressing cells using borosilicate pipettes (3-5 MΩ) containing (in mM): 130 K-gluconate, 6.3 KCl, 0.5 EGTA, 10 HEPES, 4 Mg-ATP, 0.3 Na-GTP and 0.3% biocytin (pH adjusted to 7.3 with KOH). Upon break-in, series resistance (typically 15-25 MΩ) was compensated and only stable recordings (<20% change) were included. Data were acquired using a MultiClamp 700B amplifier (Molecular Devices), sampled at 20 kHz and filtered at 10 kHz. All cells were held at −60 mV with a DC current, and current-step protocols were applied to obtain firing patterns and to extract basic sub-and suprathreshold electrophysiological properties.
Voltage clamp. dTomato-negative cells were selected according to their pyramidal-cell-shaped soma under IR-DIC visualization and recorded with pipettes containing (in mM): 130 Cs-gluconate, 0.5 EGTA, 7 KCl, 10 HEPES, 4 Mg-ATP, 0.3 Na-GTP, 5 phosphocreatine, 5 QX-314 and 0.3% biocytin (pH adjusted to 7.3 with CsOH). Cells were held continuously at 0 mV for baseline and CNO application. For both current and voltage clamp recording, a baseline of at least 2 min was recorded before CNO (500 nM) was bath applied for at least 5 min. Small pulses (−20 pA or −5 mV, 100 ms at 0.2 Hz or 0.5 Hz) were applied throughout the baseline and CNO application to monitor series resistance changes. Data were analyzed offline using Clampfit 10.2 software (Molecular Devises).
Morphological identification. To confirm the morphology of recorded cells, slices were fixed for 1 h in 4% PFA following the recording and then in 30% sucrose for storage. For biocytin staining, slices were washed with PBS and incubated with streptavidin-conjugated Alexa Fluor (1:500) and 0.3% Triton X-100 in PBS overnight. Slices were then washed with PBS and mounted on microscope slides. Confocal image stacks were acquired using a Zeiss LSM510 microscope with a 20× objective. electrophysiological recordings in zebra finches. Slice preparation. All extracellular solutions were adjusted to 310 mOsm, pH 7.3-7.4, and aerated with a 95%/5% O 2 /CO 2 mix. Zebra finches were first deeply anesthetized with an intramuscular injection of pentobarbital (40 mg/kg in saline). Once the animal was no longer responsive to a toe pinch, it was quickly decapitated, and the brain was removed from the skull and submerged in cold (1-4 °C) oxygenated zero-sodium ACSF containing the following (in mM): 225 sucrose, 3 KCl, 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 10 d-(+)-glucose, 2 MgSO 4 , 2 CaCl 2 . The brain was then cut along the sagittal plane and the medial side of the right hemisphere was glued onto a custom-made slice block. The block was constructed such that the vibratome blade entered the brain posteriorly at a 12° angle of elevation with respect to the glued medial side. Slices (300 m) containing HVC were produced using a vibratome (VT1200S; Leica) outfitted with a ceramic blade (Cadence) and an advancing speed of 0.12 mm/s. After cutting, slices were transferred to a recovery chamber at a temperature of 32 °C for 25 min with reduced sodium ACSF containing the following (in mM): 60 NaCl, 75 sucrose, 2.5 KCl, 1.2 NaH 2 PO 4 , 30 NaHCO 3 , 25 d-(+)-glucose, 20 HEPES, 2 MgSO 4 and 2 CaCl 2 . The slices remained in the recovery chamber for at least another 40 min at room temperature (23 °C) before electrophysiological recording.
Current-clamp recording. Whole-cell current-clamp recordings were obtained from visually identified GFP-expressing cells using borosilicate pipettes (3-5 MΩ) containing (in mM): 0.2 EGTA, 130 K-gluconate, 4 KCl, 2 NaCl, 10 HEPES, 4 ATP-Mg, 0.3 GTP-Tris, 14 phosphocreatine-Tris, 0.3% biocytin and brought to pH 7.25 and 292 mOsm. Upon break-in, series resistance (typically 15-25 MΩ) was compensated and only stable recordings (<20% change) were included. Data were acquired using a MultiClamp 700B amplifier, sampled at 20 kHz and filtered at 10 kHz. Current steps protocols were applied to obtain the firing pattern and to extract basic sub-and suprathreshold electrophysiological properties. Neuronal cell bodies were visualized for recording using an Axio Examiner A1 (Zeiss) fixed-stage upright microscope using IR-Dodt illumination through a 40× water-immersion objective. GFP positive neurons were targeted under visual-guidance fluorescing in the free wavelength using an Axiocam MRm fluorescence camera (Zeiss).
Morphological identification. To confirm the morphology of recorded cells, slices were fixed for 1 h in 4% PFA following the recording and then in 30% sucrose for storage. For biocytin staining, slices were washed with PBS and incubated with streptavidin-conjugated Alexa Fluor (1:500) and 0.3% Triton X-100 in PBS overnight. Slices were then washed with PBS and mounted on microscope slides. Confocal image stacks were acquired using a Zeiss LSM510 microscope with a 20× objective.
Two-photon targeted whole-cell recordings. On the day of recording, a small hole (~100 µm in diameter) was carefully drilled into the implanted cover slip using a carbide bur (0.3 mm in diameter) just lateral to the visually determined center of HVC and the recording was performed as previously described 47 .
optogenetics and electrophysiological recordings in gerbils. Slice preparation. Thalamo-cortical brain slices (500 µm thick) were prepared as previously described 48 .
Current clamp recording. The ACSF contained (in mM): 125 NaCl, 4 KCl, 1.2 KH 2 PO 4 , 1.3 MgSO 4 , 24 NaHCO 3 , 15 glucose, 2.4 CaCl 2 , and 0.4 L-ascorbic acid and bubbled with 95%O 2 -5%CO 2 (pH 7.3). Before each whole-cell recording, the auditory cortex was identified by extracellular field responses evoked by stimulation of the auditory thalamus (Medial Geniculate Nucleus).
Whole-cell current-clamp optogenetic recording. Current-clamp recordings were obtained from pyramidal, fast-spiking and low-threshold-spiking neurons in L2/3 of the ACx. Each neuron was verified as thalamo-recipient by recording an MGevoked response, and all data were collected within layer 2/3. The internal recording solution contained (in mM): 5 KCl, 127.5 K-gluconate, 10 HEPES, 2 MgCl 2 , 0.6 EGTA, 2 ATP, 0.3 GTP and 5 phosphocreatine (pH 7.2 with KOH). The tip resistance of the patch electrode filled with internal solution was 5-10 MΩ. Access resistance was 15-30 MΩ and was compensated by ~70%. All data were acquired at a sampling rate of 10 kHz using a custom-designed IGOR (version 4.08; WaveMetrics, Lake Oswego, OR) macro on an iMac (Apple, Cupertino, CA). A second IGOR macro was used for offline analysis. Firing profiles were evaluated on the basis of responses to positive current pulses (1,500 ms) of 400 to 600 pA. For pyramidal neurons, inhibitory postsynaptic potentials (IPSPs) were evoked by passing positive current (400 to 600 pA) for 1.5 s coupled with 1 ms of blue light (20% intensity, 470 nm, lumen 1,600-lumen LED: Olympus) at 500 ms. Putative inhibitory cells (fluorescing) were patched using IR-IDC and mCherry filters. Threshold to action potential was achieved by gradually increasing light (470 nm) exposure (1 ms) from 0 to 20% intensity. Input-output functions were gathered by exposing the cell to increasing intensity of light (470 nm) exposure (1 ms) from 0 to 100% in 10% steps. All neuronal images were collected in vitro with a fluorescent camera (QImaging) equipped with an mCherry filter cube (Olympus) using QCapture Pro (QImaging). calcium imaging in mouse primary culture and in ferrets. GCaMP6f imaging were performed as previously described 43, 49 . For primary culture, rAAV-mDlx-GCaMP6f (titer was 1 × 10 12 vg/ml, 1 µl per well in 24-well plate) was added to neuronal cultures at DIV 8, and GCaMP imaging was performed 11 d after infection.
Immunohistochemistry. Citations with validation data for each antibody are reported on the providers' websites. For primary culture of mice neurons, iPSCderived neuronal cultures and hESC-derived neuronal culture, neurons were fixed by incubation with 4% paraformaldehyde and 4% sucrose in phosphatebuffered saline (PBS) at room temperature for 5 min and then washed three times with PBS. Fixed neurons were permeabilized with 0.1% Triton X-100/PBS for 5 min, washed three times with PBS, and incubated in blocking buffer (3% bovine serum albumin plus 10% normal goat serum in PBS) for 1 h. The cells were then incubated overnight in blocking buffer with the indicated combination of the following primary antibodies at 4 °C: rabbit anti-GFP at 1:1,000 (Invitrogen, A6455, USA); mouse anti-GAD67 at 1:1,000 (Millipore, 1G10.2, USA); mouse anti-Stem-121 (Clontech, Y40410, USA); mouse anti-GABA at 1:1,000 (Sigma, A0310, USA). The cells were then washed three times with PBS and incubated with Alexa conjugated secondary antibodies (Invitrogen, USA). Animals injected with the virus were euthanized with Euthasol (Virbac, USA)
